A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
NCT01871727
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
112
Enrollment
INDUSTRY
Sponsor class
Conditions
Persistent or Recurrent Cutaneous T-Cell Lymphoma
Interventions
DRUG:
E7777 9 mcg/kg
Sponsor
Eisai Inc.
Collaborators
[object Object]
[object Object]